RxDoctor Payments Data

Lawrence Jacobson, MD

Ophthalmology · Brooklyn, NYNPI 1184627465

Payments from drug & device makers

$648in general payments, 2019–2025

Across 24 payments — averaging $26.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$261
  • Glaukos Corporation$161
  • Eyevance Pharmaceuticals LLC$69
  • Sun Pharmaceutical Industries Inc.$41
  • Oyster Point Pharma, Inc.$35
  • Ivantis, Inc$25
  • plus $57 from 3 others

What the payments were for

  • Food & beverage$648100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$648 in reported general payments places this provider in the 40th percentile of 1,587 ophthalmology providers in New York.

See all ophthalmology providers in New York

Medicare billing

Part B allowed, 2024
$163,316
Medicare patients
458
Services billed
1,933

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LumiganBimatoprost70$34,407
RestasisCyclosporine25$22,288
ProlensaBromfenac Sodium45$14,283
RocklatanNetarsudil Mesylat/Latanoprost33$11,292
RhopressaNetarsudil Mesylate13$9,569
MieboPerfluorohexyloctane/Pf12$8,702
CombiganBrimonidine Tartrate/Timolol27$8,647
Bromfenac Sodium58$7,255
Brimonidine Tartrate47$6,465
IlevroNepafenac17$6,045
SimbrinzaBrinzolamide/Brimonidine Tart25$5,712
VyzultaLatanoprostene Bunod11$4,973
Cyclosporine11$4,662
Prednisolone Acetate147$3,919
Ketorolac Tromethamine95$3,645

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLumigan, Restasis, Combigan$261$65,342122 claims
Aerie Pharmaceuticals, Inc.Rocklatan, Rhopressa$17$20,86146 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 1,587 ophthalmology providers in New York.

Other ophthalmology in Brooklyn

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →